Getting to treatment earlier.
Getting to treatment earlier.
CTD refers to a variety of autoimmune disorders with signs and symptoms that overlap with various other diseases, making diagnosis very difficult. That’s why we offer a comprehensive line of test options including NOVA Lite®, QUANTA Lite®, and QUANTA Flash® assays. We continue to develop new assays to help diagnose and stratify CTD disorders, like HMGCR for necrotizing myopathy.
- Giving patients earlier answers.Patients gain confidence when their diagnosis is supported by clinical labs results. New biomarkers like HMGCR offer help confirm a diagnosis in areas such as necrotizing myopathy where existing tests don’t cover all forms of the disease.
- Improving workflow in the lab.Assays like QUANTA Flash dsDNA, utilize random access testing to eliminate batching and improve efficiency in your lab.
- Enhancing clinical diagnosis and assessment.Clinicians appreciate the excellent performance characteristics of our CTD assays to aid in the assessment of complex symptoms and diseases.
Reagentia
QUANTA Lite® (ELISA)
QUANTA Flash® (CIA)
NOVA Lite® (IFA)
NOVA Lite® HEp-2 IgG (FC Specific)
NOVA Lite® HEp-2 IgG (FC Specific)
NOVA Lite® Rat Liver, Kidney, Stomach
NOVA Lite® Rat Liver, Kidney, Stomach
NOVA Lite® dsDNA Crithidia luciliae
NOVA Lite® ANA KSL Mouse Kidney/Stomach/Liver
NOVA Lite® ANA Plus Mouse Kidney & Stomach
NOVA Lite® dsDNA Crithidia luciliae
NOVA Lite® ANA KSL Mouse Kidney/Stomach/Liver